KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacific Biosciences Of California (PACB) Return on Sales (2016 - 2025)

Pacific Biosciences Of California has reported Return on Sales over the past 16 years, most recently at 0.9% for Q4 2025.

  • Quarterly results put Return on Sales at 0.9% for Q4 2025, down 96.0% from a year ago — trailing twelve months through Dec 2025 was 3.41% (down 140.0% YoY), and the annual figure for FY2025 was 3.41%, down 140.0%.
  • Return on Sales for Q4 2025 was 0.9% at Pacific Biosciences Of California, up from 0.99% in the prior quarter.
  • Over the last five years, Return on Sales for PACB hit a ceiling of 0.06% in Q4 2024 and a floor of 11.47% in Q1 2025.
  • Median Return on Sales over the past 5 years was 1.49% (2024), compared with a mean of 2.17%.
  • Peak annual rise in Return on Sales hit 376bps in 2025, while the deepest fall reached -945bps in 2025.
  • Pacific Biosciences Of California's Return on Sales stood at 1.92% in 2021, then crashed by -60bps to 3.08% in 2022, then surged by 54bps to 1.41% in 2023, then soared by 104bps to 0.06% in 2024, then plummeted by -1596bps to 0.9% in 2025.
  • The last three reported values for Return on Sales were 0.9% (Q4 2025), 0.99% (Q3 2025), and 1.05% (Q2 2025) per Business Quant data.